DiaSorin (FTSE MIB: DIA) announced in a release the FDA 510(k) clearance and the commercial launch in the US of the host-protein signature-based assay LIAISON MeMed BV.
The launch follows a Licensing Agreement signed with MeMed that was announced in September 2020, under which DiaSorin obtained the rights to commercialize and make the MeMed BV test available on the extensive installed base of LIAISON platforms.
The LIAISON MeMed BV test utilizes host responsebased data to enable physicians to differentiate between bacterial and viral infections, supporting fast and better-informed treatment and patient management decisions. The test also drives laboratory operational efficiency through time-labor reduction by using a fully automated and high-throughput approach when compared with traditional growth based microbiology methods.
